Advances in acute and chronic pancreatitis  

作　　者：Williamson B Strum Clement Richard Boland 

机构地区：[1]Department of Gastroenterology,Scripps Clinic,La Jolla,CA 92037,United States [2]Department of Medicine,University of California San Diego,La Jolla,CA 92037,United States

出　　处：《World Journal of Gastroenterology》2023年第7期1194-1201,共8页世界胃肠病学杂志（英文版）

摘　　要：Acute pancreatitis(AP)and chronic pancreatitis are the third leading gastrointestinal causes for admissions and readmissions to hospitals in the United States.This review of articles published between 2019-2022(December)from international sources identified four categories of crucial new findings:The report includes(1)New genetic pathogenic mutations(TRPV6);expected genetic outcomes in a Northern European population;(2)a new serum diagnostic marker for AP-fatty acid ethyl esters-distinguishing acute pancreatitis associated with alcohol;explanations of the impact of monocytes/macrophages on the inflammatory process that defines their future in diagnosis,staging,and treatment;(3)innovations in timing of per os low-fat,solid food intake immediately on admission;resolution of concepts of aggressive parenteral fluid intake;dramatic shifts to nonoperative from operative treatment of infected pancreatic necrosis.Each modification reduced interventions,complications,and lengths-of-stay;and(4)authoritarian recommendations for medical treatment of chronic pain.These advances offer opportunities to initiate newly proven treatments to enhance outcomes,alter the natural history,and envision the future of two diseases that have no known cure.

关 键 词：GENETICS New diagnostics Macrophage regulation New approaches to early feeding Fluid management 

分 类 号：R576[医药卫生—消化系统]